BioCardia (BCDA) Q3 2026 earnings review
BioCardia clears regulatory steps, but its cash nears exhaustion
BioCardia cleared its final pre-filing steps with Japanese regulators while its cash balance shrank toward year-end exhaustion. The heart-therapy developer spent $1.7 million in cash during the third quarter, cutting cash on hand by 46% to $2.2 million. Chief executive Peter Altman said its CardiAMP cell therapy stays on track for Japan, where the company hired its required local regulatory agent, and the FDA agreed on a standalone review path for the Helix delivery catheter.
| Cash and cash equivalents | $2.2M down 46% from last quarter |
|---|---|
| Quarterly operating cash burn | $1.7M 1.3 quarters of cash left by our math |
| Weighted-average share count | 15.1M +141% from a year ago |
| Japan CardiAMP filing target | Q4 26 / Q1 27 widened from Q4 2026 |
⚖️ Verdict: 🔴 Bearish
The story got worse because the target window for the Japanese marketing application slipped into early 2027 just as cash dropped to roughly four months of spending by our math. Stockholders' equity also fell 69% from June to $835,000 after a $1.8 million net loss that included higher bonus accruals. On the positive side, answering the Japanese agency's pre-submission questions and getting formal FDA minutes for Helix remove key regulatory obstacles.
The question now is how BioCardia pays its bills between January 2027 and its planned first-quarter regulatory filings. Either the company signs a Japanese or device partnership that brings upfront cash, or it must issue more stock under tight small-company fundraising limits. A financing or partnering announcement before year-end will settle it.
🐂 Bull Case
Japan Regulators Cleared Final Pre-Filing Questions
CardiAMP is BioCardia's cell therapy that uses a patient's own bone marrow cells to treat heart failure. Chief executive Peter Altman wants Japan to be the company's first commercial market, and he said CardiAMP is on track to be the first minimally invasive biologic heart failure treatment approved in a developed nation.
In November, the developer of heart therapies finished its pre-application review with Japan's Pharmaceuticals and Medical Devices Agency (PMDA), the country's health regulator. The agency agreed that all pre-submission questions were answered. BioCardia also "engaged a Designated Marketing Authorization Holder, or DMAH, as the local regulatory representative required for foreign medical device and pharmaceutical companies seeking to sell products in Japan without establishing a local office".
Those steps remove the regulatory hurdles that blocked an application, because a foreign company cannot file in Japan without a local holder and agency sign-off on its trial format. However, contractors still must audit the clinical sites and format the trial records before the company can submit.
What to watch: formal acceptance of the Japanese marketing application by the PMDA, targeted for late 2026 or early 2027. Acceptance will start the official review clock and show that data formatting caused no new delays.
FDA Aligned on a Standalone Helix Filing Path
Helix is BioCardia's catheter system for injecting biologic therapies directly into heart muscle. Management wants US approval for Helix on its own so the company can sell or license the device to other drug developers before CardiAMP finishes its US trials.
In August, the US Food and Drug Administration (FDA) accepted the Q2 meeting summary as "formal minutes without changes" for a standalone De Novo device application. BioCardia sent a revised pre-submission package in September, which the agency accepted in October with feedback due within six weeks. That keeps the catheter on track for a first-quarter 2027 filing and a mid-2027 approval decision if regulators meet their 150-day review goal.
What to watch: written FDA feedback on the revised Helix pre-submission in the fourth quarter of 2026. Clean feedback will allow BioCardia to submit the full marketing application in the first quarter of 2027.
Positives this quarter didn't test
One standing positive driver from earlier quarters received no new information in the third-quarter press release.
- Japanese treatment pricing: management previously pointed to a competitor's $326,000 reimbursement rate in Japan as a reference point above its old $20,000 estimate, and official pricing discussions with Japanese health authorities after an approval will test that figure.
🐻 Bear Case
Cash Covers Just Four Months of Spending
BioCardia has no product revenue and funds its clinical trials from its cash balance. The company said it ended September with $2.2 million in cash, "providing anticipated runway into 2027". Simultaneously, management widened the target window for its Japanese CardiAMP application from the fourth quarter of 2026 to include the first quarter of 2027.
Operations used $1.7 million of cash in the third quarter, cutting the cash balance by 46% from $4.1 million in June. By our math, $2.2 million covers just 1.3 quarters — about four months — at that $1.7 million quarterly spending pace, and current liabilities already sit at $2.1 million.
This math cuts against the comfort of the company's "into 2027" wording, because "into 2027" means January 2027 at current spending rates. Because the Japanese filing, the Helix FDA application, and the Heart3D imaging submission now cluster in the first quarter of 2027, the company must raise cash or sign a partner deal before its major regulatory filings happen.
What to watch: a financing announcement or partnering deal with upfront cash before January 2027. Without fresh funds, BioCardia cannot pay for operations through its first-quarter 2027 regulatory submissions.
Share Count More Than Doubled as Equity Shrank
Because BioCardia earns no commercial revenue, it issues new stock to pay for its operations and maintain its stock exchange listing. Those share sales shrink each existing shareholder's stake in future drug royalties.
- Weighted-average share count: 15.1 million in Q3, up 141% from 6.3 million a year ago and up 25% from Q2
- Stockholders' equity: $835,000 at September 30, down 69% from $2.7 million at June 30 by our math
- Net loss per share: $0.12, cut in half from $0.24 a year ago even though the total net loss grew 23% to $1.8 million
The per-share loss shrank only because the share count more than doubled after June's stock sales. Worse, the $1.8 million quarterly loss wiped out most of the stockholders' equity rebuilt in the second quarter, leaving equity at $835,000 and putting Nasdaq listing compliance back in play.
What to watch: stockholders' equity and total share count in the full 2026 annual report. Another quarter without equity financing will push stockholders' equity into a deficit by year-end.
US Heart Failure Trial Added Zero Active Sites
CardiAMP HF II is BioCardia's confirmatory US Phase 3 trial for heart failure. After the first US study missed its primary goal, the FDA told the company that this second study will serve as the main evidence for US approval.
BioCardia said four clinical sites are actively recruiting patients while seven more are being set up. However, the count of four active sites has not budged since the third quarter of 2025, and the company still does not disclose how many patients have enrolled. Despite the flat active site count, research and development spending rose 32% from a year ago to $1.2 million, driven by a "bonus accrual at a higher level" alongside Japanese filing preparation.
What to watch: the number of active clinical sites and total patients enrolled in the next quarterly update. Until those seven new hospitals start recruiting, US approval remains years away.
Risks this quarter didn't answer
Three standing financing and operational risks were not addressed in the third-quarter earnings release.
- Exhausted at-the-market stock facility and baby-shelf fundraising limits: the footnotes of the third-quarter 10-Q filing will show whether any new credit line or share sale agreement is in place.
- Warrant overhang of roughly 7.8 million shares: the 10-Q capitalization table will show whether any warrants were exercised or repriced.
- Headquarters and lab lease expiring in January 2027: the 10-Q lease footnote will show whether management signed an extension.
💲 Other KPIs
Overhead spending rose 8.7% from $552,000 a year ago, reversing three straight quarters of year-over-year declines. Compared with the second quarter of 2026, overhead costs fell 17.8% from $730,000 by our math. For the first nine months of 2026, overhead spending totaled $2.36 million, down 2.9% from $2.43 million in the prior year.
Bills due within one year edged up 1.8% from $2.06 million at the end of June by our math, after falling from $2.43 million at the end of 2025. Because cash dropped to $2.22 million, cash exceeds current liabilities by just $132,000 at quarter-end.
Cash used in operations over the first nine months of 2026 increased 4.1% from $4.9 million in the same period a year ago by our math. The medical device and cell therapy developer said the increase came from the timing of supplier payments.
🔮 Guidance
Unchanged. BioCardia still says its $2.2 million cash balance will fund operations into 2027. By our math, at the third quarter's $1.7 million cash burn rate, $2.2 million lasts about 1.3 quarters, which reaches January 2027. Management has extended its cash horizon four times over the past two years, each time only after selling new stock.
Pushed out. The cell therapy maker widened its target window for submitting the Japanese CardiAMP marketing application to include the first quarter of 2027, after previously targeting the fourth quarter of 2026. Contractors are still auditing clinical sites and formatting trial records into regulatory standards before the filing can go in.
Pushed out. Management now targets the first quarter of 2027 to publish the peer-reviewed paper on its completed first heart failure trial. A year ago, the company targeted the first quarter of 2026 for this publication.
On track. Following the FDA's October acceptance of the revised pre-submission package for the Helix delivery catheter, the group expects written feedback or a meeting in the fourth quarter of 2026, within six weeks of the November 12 release. That sets up a planned full De Novo marketing submission in the first quarter of 2027.
New. BioCardia issued first-quarter 2027 targets for submitting its Heart3D imaging software to the FDA and starting a gene therapy study with partners using both Helix and Heart3D.
❓ Key Questions
How will BioCardia fund operations past January 2027?
Cash of $2.2 million covers roughly four months of spending at the $1.7 million quarterly pace, and the at-the-market share sale facility was exhausted in June. Investors need to know whether a licensing deal with upfront cash or an equity offering will close before year-end.
Why did R&D bonus accruals rise while cash ran low?
Research and development spending jumped 32% from a year ago to $1.2 million partly due to a higher bonus accrual, even as cash fell to $2.2 million and the Japanese filing window widened into early 2027. Management did not explain what milestones triggered those bonuses.
How many patients have enrolled in CardiAMP HF II?
Active recruiting sites for the confirmatory US trial have stayed flat at four for a full year while seven more sites work through onboarding. Without total patient enrollment numbers, investors cannot judge when the US trial will finish.
Does the $835,000 equity balance trigger a Nasdaq warning?
Stockholders' equity dropped 69% in the third quarter to $835,000, well below the $2.5 million minimum typically required for Nasdaq Capital Market continued listing. Management has not stated whether the company meets an alternative listing standard.